ECOG E6508: A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation

Print this page

ECOG E6508: A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation

The primary objective is to determine the safety of combination therapy with chemoradiation, followed by consolidation, finally followed by L-BLP25 and bevacizumab for patients with non-squamous, locally advanced NSCLC.
The secondary objectives are to evaluate overall survival, toxicity, and progression-free survival for patients treated with L-BLP25 plus bevacizumab in addition to chemoradiation and consolidation therapy.
The laboratory endpoints of this study will attempt to determine the fraction of circulating dendritic cells and immature myeloid cells before, during and after maintenance treatment and to determine the ability of dendritic cells to induce an allogenic mixed lymphocyte reaction in vivo.

Protocol Number031101
Principal InvestigatorJoseph Aisner
PhasePhase II
ScopeNational
Applicable Disease SitesLung
Therapies InvolvedChemotherapy multiple agents systemic
Radiotherapy
Drugs InvolvedBEVACIZUMAB
PACLITAXEL
CARBOPLATIN
Participating InstitutionsRutgers Cancer Institute of New Jersey
Robert Wood Johnson University Hospital at Hamilton

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.